Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A compound containing nitrobenzene and diene adamantane structure, its preparation method and application

A compound and diene technology, applied in the field of drugs related to thrombotic diseases, can solve problems such as high bleeding risk

Active Publication Date: 2016-08-24
HONGGUAN BIO PHARMA CO LTD
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The disadvantage of these drugs is the greater risk of bleeding

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound containing nitrobenzene and diene adamantane structure, its preparation method and application
  • A compound containing nitrobenzene and diene adamantane structure, its preparation method and application
  • A compound containing nitrobenzene and diene adamantane structure, its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021]

[0022] 2.43g (10mmol) compound II and 2.62g (10mmol) PPh 3 Dissolve in 20 mL of dry THF and reflux overnight under nitrogen protection. After the reaction mixture was cooled to room temperature, a white cloudy solution was obtained. Cooled to -78°C under nitrogen protection, slowly added 6.25mL (10mmol, 1.6M) n-BuLi n-hexane solution dropwise. After the dropwise addition was completed, stirring was continued for one hour, and a solution prepared by dissolving compound 1.28g (10mmol) III in 2mL of THF was added dropwise. After the dropwise addition was complete, the reaction mixture was slowly warmed to room temperature and then refluxed for 1 hour. The reaction mixture was poured into ice water, stirred, extracted with 50 mL×3 dichloromethane, the combined extracts were washed with brine, and dried over anhydrous sodium sulfate. The desiccant was removed by suction filtration, 0.50 g of iodine was added to the filtrate, and stirred overnight at room temperature....

Embodiment 2

[0025] The preparation of embodiment 2 reference compound D1

[0026] In order to fully illustrate the beneficial effects of the compounds of the present invention, the applicant recorded the following compound D1 (unpublished) found during the experiment as a pharmacodynamic reference compound.

[0027]

[0028] The synthesis method is as follows:

[0029]

[0030] 2.43g (10mmol) compound II and 2.62g (10mmol) PPh 3 Dissolve in 20 mL of dry THF and reflux overnight under nitrogen protection. After the reaction mixture was cooled to room temperature, a white cloudy solution was obtained. Cooled to -78°C under nitrogen protection, slowly added 6.25mL (10mmol, 1.6M) n-BuLi n-hexane solution dropwise. After the dropwise addition was completed, stirring was continued for one hour, and a solution prepared by dissolving compound 1.28g (10mmol) III in 2mL of THF was added dropwise. After the dropwise addition was complete, the reaction mixture was slowly warmed to room temp...

Embodiment 7

[0033] Example 7 In vitro platelet aggregation inhibition test

[0034]Pharmacological tests of substances were performed in TRAP (thrombin receptor activating peptide)-induced platelet aggregation in 96-well plates. A 3.13% sodium citrate solution was pre-added into the syringe, and then 20 mL of blood from healthy volunteers was drawn in, centrifuged at 1500 g for 20 minutes, and the platelet-rich plasma (PRP) was separated and mixed with 1 μL of PGE1 solution (500 μg / mL ethanol solution) / mL PRP for treatment. After incubation at room temperature for 5 minutes, they were centrifuged at 1200 g for 20 minutes to remove leukocytes. Transfer the leukocyte-free PRP to 15 mL PP tubes in batches at 5 mL / portion, and centrifuge at 3600 g to pellet the platelets. Then, decant the upper plasma layer and resuspend the platelet pellet from 5 mL of PRP in 1 mL of Tyrode (120 mM NaCl, 2.6 mM KCl, 12 mM NaHCO 3 , 0.39mM NaH 2 PO 4 , 10 mM HEPES, 0.35% BSA, 5.5 mM glucose, pH=7.4), and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicine related to thrombotic diseases, in particular to a PAR-1 antagonist shown in the specification and containing a nitrobenzene and diene adamantine structure and a preparation method and application of the PAR-1 antagonist.

Description

technical field [0001] The invention relates to the field of drugs related to thrombosis diseases. Specifically, the present invention relates to a PAR-1 antagonist containing nitrobenzene and diene adamantane structure, which has a therapeutic effect on thrombotic diseases, and a preparation method thereof, a pharmaceutical composition containing them and a method for treating thrombotic diseases. Uses above. Background technique [0002] Protease Activated Acceptor-1 (PAR-1) is a new target of anti-platelet antithrombotic drugs discovered recently. Protease-activated receptor 1 is also called thrombin receptor. After thrombin is activated by the coagulation chain, it acts on platelets through PAR-1 receptors to activate platelets, causing platelet aggregation and causing thrombus and coagulation. The thrombus induced by PAR-1 is rich in platelet components, which is the main cause of arterial thrombus. PAR-1 antagonists can block thrombin from activating platelets, ther...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D207/335A61K31/402A61P7/02A61P9/10
CPCC07D207/335
Inventor 蔡子洋
Owner HONGGUAN BIO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com